Enalare Therapeutics Completes Formation of Its Scientific Advisory Board Posted Jan 13, 2021
The Appointments of Professors Albert Dahan MD, PhD and Tong Joo (TJ) Gan MD, MHS, MBA Highlight a World Class Collection of Medical and Pharmaceutical Industry Experts
PRINCETON, N.J., January 12, 2021 – Enalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from acute respiratory conditions, announced today that it has completed formation of its scientific advisory board. The Company is very pleased to welcome Albert Dahan MD, PhD, Tong Joo (TJ) Gan MD, Robert Raffa PhD, Eugene Vortsman DO, David Battleman MD, and Alexander Krause PhD to the organization as it advances the development of its lead product ENA-001 for several life-threatening indications involving respiratory depression.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Scopus BioPharma Announces Appointment of Additional Directors
December 29, 2020 GMT
(PRNewsfoto/Scopus BioPharma Inc.)
NEW YORK, Dec. 29, 2020 /PRNewswire/ Scopus BioPharma Inc. (Nasdaq: SCPS) today announced the appointment of additional members to its Board of Directors. Scopus is a biopharmaceutical company whose lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers.
Joshua R. Lamstein, Chairman of Scopus BioPharma, stated, “We are delighted to be in a position to attract prominent industry leaders to our Board. Our new directors are well-recognized for their leadership and accomplishments in the biopharmaceutical, biotechnology and pharmaceutical industries, as well as in public capital markets and corporate governance.”